Bayer Schering Pharma AG, Germany, highlighted their expanded new offerings in Men's Healthcare during a press conference held at the 22nd Annual Meeting of the European Association of Urology (EAU) on March 22, 2007. The event focused on study results from their three products: Levitra(R), Testogel(R) and Nebido(R).

The Real-Life Perception of Efficacy, Attitude, Satisfaction and Safety of Levitra(R) Therapy (REPEAT) study(1) has been designed to help researchers determine why over 50% of couples experiencing sexual problems discontinue treatment and the levitra side effects. This three year, innovative post marketing surveillance (PMS) study will follow men treated with Levitra(R) and their female partners in over 20 countries for 12 months. Understanding the couple's attitude, perception and behaviour during treatment are crucial to good outcomes in PDE-5 therapy such as Levitra(R).

Bayer Schering Pharma will use results from REPEAT as a part of their award-winning patient education programmes to help couples continue on treatment. This study is a further example of Bayer Schering's commitment to ensure that Levitra(R) helps couples around the world; and follows on from the world-wide release of the very positive results of the Real-Life Safety and Efficacy of Vardenafil (REALISE) study(2). The REALISE study, the largest study of erectile dysfunction (ED) in the world, a PMS study covering 50 countries, 30,000 investigators and over 100,000 patients showed Levitra(R) to be efficacious and safe when used in the real-world.

The results obtained from REPEAT will be extremely useful in understanding the interaction between patient, partner and physician when seeking treatment for erectile problems and what can be done to assist men and their partners to achieve optimal results. More importantly, it will help us to establish why some men discontinue treatment even though they continue to suffer from ED. ED can have a huge impact on a relationship and exploring these issues will help healthcare professionals to assist their patients to choose the best treatment" said Hermann Van Ahlen, MD, Professor of Urology, University of Muenster, Germany.

Levitra(R) is a proven ED treatment to help men and their partners. The COUPLES study(3), also released today at the EAU, compares patient and partner satisfaction with Levitra(R) as measured by the TSS (Treatment Satisfaction Scale) by exploring pooled results of three multi-centre 12-week randomised, double-blind, placebo-controlled studies of flexible-dose vardenafil versus placebo. Couples agree that Levitra(R) provided significantly greater satisfaction versus placebo and that satisfaction is achieved by not only to the man, but also to his partner.

Source::
http://www.pr-inside.com/